Phaseline

Companies › Fulgent Pharma

Fulgent Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FID-022
SN38 and irinotecan (prodrug of SN38) encapsulated with polyethyloxazoline (PEOX)
–Phase 1Advanced Solid TumorsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06694480FID-022Phase 1Advanced Solid TumorsOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.